Becton Dickinson and Company (BDX)vsSTAAR Surgical Company (STAA)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
STAA
STAAR Surgical Company
$19.19
+1.16%
HEALTHCARE · Cap: $950.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 9056% more annual revenue ($21.92B vs $239.44M). BDX leads profitability with a 8.0% profit margin vs -33.6%. STAA appears more attractively valued with a PEG of 0.76. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
STAA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for STAA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
18.1% revenue growth
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -21.7% — below average capital efficiency
Earnings declined 10.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : STAA
The strongest argument for STAA centers on Debt/Equity, PEG Ratio, Price/Book. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : STAA
The primary concerns for STAA are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
BDX profiles as a value stock while STAA is a growth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.05 — expect wider price swings.
STAA is growing revenue faster at 18.1% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?